Esperion (ESPR) is a small company developing a cholesterol drug with the aim to succeed Lipitor or at least to complement it. It is facing up to pharma giants like Sanofi, Amgen and Pfizer. But the company has one asset that nobody else does: its executive chairman is the one and only Roger Newton, an icon of the cholesterol business.
In September Esperion announced positive top-line results from a Phase 2a study of its drug, ETC-1002 when added to statin therapy in patients with elevated levels of low density LDL-C or "bad cholesterol".
Later in 2013 Esperion is planning a larger Phase 2b trial targeting the statins intolerant population with results expected in 2014.
Only subscribers can access this article, which is part of the PRO research library covering 3,770 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: